학술논문
721 Ongoing phase 1 study of MP0317, a FAP-CD40 DARPin, shows a favorable safety profile and early evidence of tumor-localized CD40 activation in patients with advanced solid tumors
Document Type
article
Author
Anne Goubier; Neeltje Steeghs; Carlos Gomez-Roca; Philippe Cassier; Elena Fernandez; Eelke Gort; Hilde De Winter; Vaia Stavropoulou; Nina Stojcheva; Paul Baverel; Jennifer Krieg; Kyriaki Ioannou; Ana Maria Florescu; Lea Hoenig; Bruno Baud-Berthier; Michael P Sanderson; Vladimir Kirkin; Philippe Legenne
Source
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Subject
Language
English
ISSN
2051-1426